| 摘要 |
Disclosed is the use of glucagon for the manufacture of a medicament for reducing the risk of insulin-induced hypoglycaemia in a diabetes patient who is being treated with insulin, wherein the glucagons is formulated for administration to a patient in an amount that results in a plasma glucagon level in the range achieved by intravenous infusion of glucagon at a rate that is not less than 0.10 ng/kg/min and not more than 5.00 ng/kg/min, and wherein said glucagon is formulated for administration daily as part of a diabetes treatment regimen, and wherein said patient is not suffering hypoglycemic symptoms and has a blood glucose level of from 70-110 mg/dL.
|
